Indication: Hematological Malignancies
A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) plus Rituximab Versus Bendamustine plus Rituximab in Patients with Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation
Lymphoma
Line of Therapy: 1st line
Drug Study
Principal Investigator: Don Stevens, M.D.Norton Cancer Institute
Sponsor: BeiGene, Ltd
Learn more at ClinicalTrials.gov
Email for more information: Heme-NCIResearch@nortonhealthcare.org
